scispace - formally typeset
Search or ask a question
Author

Bader Chaarani

Other affiliations: University of Oregon
Bio: Bader Chaarani is an academic researcher from University of Vermont. The author has contributed to research in topics: Cognition & Medicine. The author has an hindex of 14, co-authored 46 publications receiving 1208 citations. Previous affiliations of Bader Chaarani include University of Oregon.

Papers published on a yearly basis

Papers
More filters
Journal ArticleDOI
TL;DR: An overview of the imaging procedures of the ABCD study is provided, the basis for their selection and preliminary quality assurance and results that provide evidence for the feasibility and age-appropriateness of procedures and generalizability of findings to the existent literature are provided.

1,114 citations

Journal ArticleDOI
TL;DR: The results indicate that dependence on a range of different substances shares a common neural substrate and that differential patterns of regional volume could serve as useful biomarkers of dependence on alcohol and nicotine.
Abstract: Objective: Although lower brain volume has been routinely observed in individuals with substance dependence compared with nondependent control subjects, the brain regions exhibiting lower volume have not been consistent across studies. In addition, it is not clear whether a common set of regions are involved in substance dependence regardless of the substance used or whether some brain volume effects are substance specific. Resolution of these issues may contribute to the identification of clinically relevant imaging biomarkers. Using pooled data from 14 countries, the authors sought to identify general and substance-specific associations between dependence and regional brain volumes. Method: Brain structure was examined in a mega-analysis of previously published data pooled from 23 laboratories, including 3,240 individuals, 2,140 of whom had substance dependence on one of five substances: alcohol, nicotine, cocaine, methamphetamine, or cannabis. Subcortical volume and cortical thickness in regions defined by FreeSurfer were compared with nondependent control subjects when all sampled substance categories were combined, as well as separately, while controlling for age, sex, imaging site, and total intracranial volume. Because of extensive associations with alcohol dependence, a secondary contrast was also performed for dependence on all substances except alcohol. An optimized split-half strategy was used to assess the reliability of the findings. Results: Lower volume or thickness was observed in many brain regions in individuals with substance dependence. The greatest effects were associated with alcohol use disorder. A set of affected regions related to dependence in general, regardless of the substance, included the insula and the medial orbitofrontal cortex. Furthermore, a support vector machine multivariate classification of regional brain volumes successfully classified individuals with substance dependence on alcohol or nicotine relative to nondependent control subjects. Conclusions: The results indicate that dependence on a range of different substances shares a common neural substrate and that differential patterns of regional volume could serve as useful biomarkers of dependence on alcohol and nicotine.

176 citations

Journal ArticleDOI
TL;DR: The results suggest that BMI is associated with prefrontal cortex development and diminished executive functions, such as working memory.
Abstract: Importance A total of 25.7 million children in the United States are classified as overweight or obese. Obesity is associated with deficits in executive function, which may contribute to poor dietary decision-making. Less is known about the associations between being overweight or obese and brain development. Objective To examine whether body mass index (BMI) is associated with thickness of the cerebral cortex and whether cortical thickness mediates the association between BMI and executive function in children. Design, Setting, and Participants In this cross-sectional study, cortical thickness maps were derived from T1-weighted structural magnetic resonance images of a large, diverse sample of 9 and 10-year-old children from 21 US sites. List sorting, flanker, matrix reasoning, and Wisconsin card sorting tasks were used to assess executive function. Main Outcomes and Measures A 10-fold nested cross-validation general linear model was used to assess mean cortical thickness from BMI across cortical brain regions. Associations between BMI and executive function were explored with Pearson partial correlations. Mediation analysis examined whether mean prefrontal cortex thickness mediated the association between BMI and executive function. Results Among 3190 individuals (mean [SD] age, 10.0 [0.61] years; 1627 [51.0%] male), those with higher BMI exhibited lower cortical thickness. Eighteen cortical regions were significantly inversely associated with BMI. The greatest correlations were observed in the prefrontal cortex. The BMI was inversely correlated with dimensional card sorting (r = −0.088,P Conclusions and Relevance These results suggest that BMI is associated with prefrontal cortex development and diminished executive functions, such as working memory.

91 citations

Book ChapterDOI
TL;DR: This chapter focuses on inhibitory control and its contribution to both current use and abstinence, with a focus on neuroimaging studies of response inhibition in current and abstinent drug abusers.
Abstract: Historically, neuroscientific research into addiction has emphasized affective and reinforcement mechanisms as the essential elements underlying the pursuit of drugs, their abuse, and difficulties associated with abstinence. However, research over the last decade or so has shown that cognitive control systems, associated largely but not exclusively with the frontal lobes, are also important contributors to drug use behaviors. Here, we focus on inhibitory control and its contribution to both current use and abstinence. A body of evidence points to impaired inhibitory abilities across a range of drugs of abuse. Typically, studies suggest that substance-abusing individuals are characterized by relative hypoactivity in brain systems underlying inhibitory control. In contrast, abstinent users tend to show either normal or supernormal levels of activity in the same systems attesting to the importance of inhibitory control in suppressing the drug use urges that plague attempts at abstinence. In this chapter, the brain and behavioral basis of response inhibition will be reviewed, with a focus on neuroimaging studies of response inhibition in current and abstinent drug abusers.

69 citations

Journal ArticleDOI
TL;DR: Evidence is presented suggesting structural brain and cognitive effects of just one or two instances of cannabis use in adolescence and Converging evidence suggests a role for the endocannabinoid system in these effects.
Abstract: Rates of cannabis use among adolescents are high, and are increasing concurrent with changes in the legal status of marijuana and societal attitudes regarding its use. Recreational cannabis use is understudied, especially in the adolescent period when neural maturation may make users particularly vulnerable to the effects of Δ-9-tetrahydrocannabinol (THC) on brain structure. In the current study, we used voxel-based morphometry to compare gray matter volume (GMV) in forty-six 14-year-old human adolescents (males and females) with just one or two instances of cannabis use and carefully matched THC-naive controls. We identified extensive regions in the bilateral medial temporal lobes as well as the bilateral posterior cingulate, lingual gyri, and cerebellum that showed greater GMV in the cannabis users. Analysis of longitudinal data confirmed that GMV differences were unlikely to precede cannabis use. GMV in the temporal regions was associated with contemporaneous performance on the Perceptual Reasoning Index and with future generalized anxiety symptoms in the cannabis users. The distribution of GMV effects mapped onto biomarkers of the endogenous cannabinoid system providing insight into possible mechanisms for these effects. SIGNIFICANCE STATEMENT Almost 35% of American 10th graders have reported using cannabis and existing research suggests that initiation of cannabis use in adolescence is associated with long-term neurocognitive effects. We understand very little about the earliest effects of cannabis use, however, because most research is conducted in adults with a heavy pattern of lifetime use. This study presents evidence suggesting structural brain and cognitive effects of just one or two instances of cannabis use in adolescence. Converging evidence suggests a role for the endocannabinoid system in these effects. This research is particularly timely as the legal status of cannabis is changing in many jurisdictions and the perceived risk by youth associated with smoking cannabis has declined in recent years.

68 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: In this article , the authors used three of the largest neuroimaging datasets currently available, with a total sample size of around 50,000 individuals, to quantify brain-wide association studies effect sizes and reproducibility as a function of sample size.
Abstract: Magnetic resonance imaging (MRI) has transformed our understanding of the human brain through well-replicated mapping of abilities to specific structures (for example, lesion studies) and functions1-3 (for example, task functional MRI (fMRI)). Mental health research and care have yet to realize similar advances from MRI. A primary challenge has been replicating associations between inter-individual differences in brain structure or function and complex cognitive or mental health phenotypes (brain-wide association studies (BWAS)). Such BWAS have typically relied on sample sizes appropriate for classical brain mapping4 (the median neuroimaging study sample size is about 25), but potentially too small for capturing reproducible brain-behavioural phenotype associations5,6. Here we used three of the largest neuroimaging datasets currently available-with a total sample size of around 50,000 individuals-to quantify BWAS effect sizes and reproducibility as a function of sample size. BWAS associations were smaller than previously thought, resulting in statistically underpowered studies, inflated effect sizes and replication failures at typical sample sizes. As sample sizes grew into the thousands, replication rates began to improve and effect size inflation decreased. More robust BWAS effects were detected for functional MRI (versus structural), cognitive tests (versus mental health questionnaires) and multivariate methods (versus univariate). Smaller than expected brain-phenotype associations and variability across population subsamples can explain widespread BWAS replication failures. In contrast to non-BWAS approaches with larger effects (for example, lesions, interventions and within-person), BWAS reproducibility requires samples with thousands of individuals.

611 citations

Journal ArticleDOI
TL;DR: An Inflammatory Biomarker as a Differential Predictor of Outcome of Depression Treatment With Escitalopram and Nortriptyline and an Antidepressant Pharmacogenetics Study in Mexican Americans is presented.
Abstract: Articles 1278 An Inflammatory Biomarker as a Differential Predictor of Outcome of Depression Treatment With Escitalopram and Nortriptyline Rudolf Uher et. al 1287 Identification and Replication of a Combined Epigenetic and Genetic Biomarker Predicting Suicide and Suicidal Behaviors Jerry Guintivano et. al 1297 Clinical Outcomes and Genome-Wide Association for a Brain Methylation Site in an Antidepressant Pharmacogenetics Study in Mexican Americans Ma-Li Wong et. al

595 citations

Journal ArticleDOI
TL;DR: In this paper , the authors used three of the largest neuroimaging datasets currently available, with a total sample size of around 50,000 individuals, to quantify brain-wide association studies effect sizes and reproducibility as a function of sample size.
Abstract: Magnetic resonance imaging (MRI) has transformed our understanding of the human brain through well-replicated mapping of abilities to specific structures (for example, lesion studies) and functions1-3 (for example, task functional MRI (fMRI)). Mental health research and care have yet to realize similar advances from MRI. A primary challenge has been replicating associations between inter-individual differences in brain structure or function and complex cognitive or mental health phenotypes (brain-wide association studies (BWAS)). Such BWAS have typically relied on sample sizes appropriate for classical brain mapping4 (the median neuroimaging study sample size is about 25), but potentially too small for capturing reproducible brain-behavioural phenotype associations5,6. Here we used three of the largest neuroimaging datasets currently available-with a total sample size of around 50,000 individuals-to quantify BWAS effect sizes and reproducibility as a function of sample size. BWAS associations were smaller than previously thought, resulting in statistically underpowered studies, inflated effect sizes and replication failures at typical sample sizes. As sample sizes grew into the thousands, replication rates began to improve and effect size inflation decreased. More robust BWAS effects were detected for functional MRI (versus structural), cognitive tests (versus mental health questionnaires) and multivariate methods (versus univariate). Smaller than expected brain-phenotype associations and variability across population subsamples can explain widespread BWAS replication failures. In contrast to non-BWAS approaches with larger effects (for example, lesions, interventions and within-person), BWAS reproducibility requires samples with thousands of individuals.

520 citations

Journal ArticleDOI
Donald J. Hagler1, Sean N. Hatton1, M. Daniela Cornejo1, Carolina Makowski2, Damien A. Fair3, Anthony Steven Dick4, Matthew T. Sutherland4, B. J. Casey5, M Deanna6, Michael P. Harms6, Richard Watts5, James M. Bjork7, Hugh Garavan8, Laura Hilmer1, Christopher J. Pung1, Chelsea S. Sicat1, Joshua M. Kuperman1, Hauke Bartsch1, Feng Xue1, Mary M. Heitzeg9, Angela R. Laird4, Thanh T. Trinh1, Raul Gonzalez4, Susan F. Tapert1, Michael C. Riedel4, Lindsay M. Squeglia10, Luke W. Hyde9, Monica D. Rosenberg5, Eric Earl3, Katia D. Howlett11, Fiona C. Baker12, Mary E. Soules9, Jazmin Diaz1, Octavio Ruiz de Leon1, Wesley K. Thompson1, Michael C. Neale7, Megan M. Herting13, Elizabeth R. Sowell13, Ruben P. Alvarez11, Samuel W. Hawes4, Mariana Sanchez4, Jerzy Bodurka14, Florence J. Breslin14, Amanda Sheffield Morris14, Martin P. Paulus14, W. Kyle Simmons14, Jonathan R. Polimeni15, Andre van der Kouwe15, Andrew S. Nencka16, Kevin M. Gray10, Carlo Pierpaoli11, John A. Matochik11, Antonio Noronha11, Will M. Aklin11, Kevin P. Conway11, Meyer D. Glantz11, Elizabeth Hoffman11, Roger Little11, Marsha F. Lopez11, Vani Pariyadath11, Susan R.B. Weiss11, Dana L. Wolff-Hughes, Rebecca DelCarmen-Wiggins, Sarah W. Feldstein Ewing3, Oscar Miranda-Dominguez3, Bonnie J. Nagel3, Anders Perrone3, Darrick Sturgeon3, Aimee Goldstone12, Adolf Pfefferbaum12, Kilian M. Pohl12, Devin Prouty12, Kristina A. Uban17, Susan Y. Bookheimer18, Mirella Dapretto18, Adriana Galván18, Kara Bagot1, Jay N. Giedd1, M. Alejandra Infante1, Joanna Jacobus1, Kevin Patrick1, Paul D. Shilling1, Rahul S. Desikan19, Yi Li19, Leo P. Sugrue19, Marie T. Banich20, Naomi P. Friedman20, John K. Hewitt20, Christian J. Hopfer20, Joseph T. Sakai20, Jody Tanabe20, Linda B. Cottler21, Sara Jo Nixon21, Linda Chang22, Christine C. Cloak22, Thomas Ernst22, Gloria Reeves22, David N. Kennedy23, Steve Heeringa9, Scott Peltier9, John E. Schulenberg9, Chandra Sripada9, Robert A. Zucker9, William G. Iacono24, Monica Luciana24, Finnegan J. Calabro25, Duncan B. Clark25, David A. Lewis25, Beatriz Luna25, Claudiu Schirda25, Tufikameni Brima26, John J. Foxe26, Edward G. Freedman26, Daniel W. Mruzek26, Michael J. Mason27, Rebekah S. Huber28, Erin McGlade28, Andrew P. Prescot28, Perry F. Renshaw28, Deborah A. Yurgelun-Todd28, Nicholas Allgaier8, Julie A. Dumas8, Masha Y. Ivanova8, Alexandra Potter8, Paul Florsheim29, Christine L. Larson29, Krista M. Lisdahl29, Michael E. Charness15, Michael E. Charness30, Michael E. Charness31, Bernard F. Fuemmeler7, John M. Hettema7, Hermine H. Maes7, Joel L. Steinberg7, Andrey P. Anokhin6, Paul E.A. Glaser6, Andrew C. Heath6, Pamela A. F. Madden6, Arielle R. Baskin-Sommers5, R. Todd Constable5, Steven Grant11, Gayathri J. Dowling11, Sandra A. Brown1, Terry L. Jernigan1, Anders M. Dale1 
TL;DR: The baseline neuroimaging processing and subject-level analysis methods used by the Adolescent Brain Cognitive Development Study are described to be a resource of unprecedented scale and depth for studying typical and atypical development.

431 citations

Journal ArticleDOI
TL;DR: This review summarizes the last decade of work by the ENIGMA Consortium, a global alliance of over 1400 scientists across 43 countries, studying the human brain in health and disease, and highlights the advantages of collaborative large-scale coordinated data analyses for testing reproducibility and robustness of findings.
Abstract: This review summarizes the last decade of work by the ENIGMA (Enhancing NeuroImaging Genetics through Meta Analysis) Consortium, a global alliance of over 1400 scientists across 43 countries, studying the human brain in health and disease. Building on large-scale genetic studies that discovered the first robustly replicated genetic loci associated with brain metrics, ENIGMA has diversified into over 50 working groups (WGs), pooling worldwide data and expertise to answer fundamental questions in neuroscience, psychiatry, neurology, and genetics. Most ENIGMA WGs focus on specific psychiatric and neurological conditions, other WGs study normal variation due to sex and gender differences, or development and aging; still other WGs develop methodological pipelines and tools to facilitate harmonized analyses of "big data" (i.e., genetic and epigenetic data, multimodal MRI, and electroencephalography data). These international efforts have yielded the largest neuroimaging studies to date in schizophrenia, bipolar disorder, major depressive disorder, post-traumatic stress disorder, substance use disorders, obsessive-compulsive disorder, attention-deficit/hyperactivity disorder, autism spectrum disorders, epilepsy, and 22q11.2 deletion syndrome. More recent ENIGMA WGs have formed to study anxiety disorders, suicidal thoughts and behavior, sleep and insomnia, eating disorders, irritability, brain injury, antisocial personality and conduct disorder, and dissociative identity disorder. Here, we summarize the first decade of ENIGMA's activities and ongoing projects, and describe the successes and challenges encountered along the way. We highlight the advantages of collaborative large-scale coordinated data analyses for testing reproducibility and robustness of findings, offering the opportunity to identify brain systems involved in clinical syndromes across diverse samples and associated genetic, environmental, demographic, cognitive, and psychosocial factors.

355 citations